TW200306839A - Quinazolinone derivatives and their use as CB agonists - Google Patents

Quinazolinone derivatives and their use as CB agonists Download PDF

Info

Publication number
TW200306839A
TW200306839A TW092102105A TW92102105A TW200306839A TW 200306839 A TW200306839 A TW 200306839A TW 092102105 A TW092102105 A TW 092102105A TW 92102105 A TW92102105 A TW 92102105A TW 200306839 A TW200306839 A TW 200306839A
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
formula
scope
patent application
Prior art date
Application number
TW092102105A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200306839A publication Critical patent/TW200306839A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092102105A 2002-02-06 2003-01-30 Quinazolinone derivatives and their use as CB agonists TW200306839A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound

Publications (1)

Publication Number Publication Date
TW200306839A true TW200306839A (en) 2003-12-01

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092102105A TW200306839A (en) 2002-02-06 2003-01-30 Quinazolinone derivatives and their use as CB agonists

Country Status (21)

Country Link
US (2) US20050085493A1 (https=)
EP (2) EP2319839A1 (https=)
JP (2) JP4428479B2 (https=)
KR (1) KR100954626B1 (https=)
CN (1) CN100579968C (https=)
AR (1) AR038483A1 (https=)
AT (1) ATE551329T1 (https=)
AU (1) AU2003210212A1 (https=)
BR (1) BR0307461A (https=)
CA (1) CA2471974C (https=)
CO (1) CO5601021A2 (https=)
EC (1) ECSP045219A (https=)
ES (1) ES2384967T3 (https=)
MX (1) MXPA04007641A (https=)
MY (1) MY143958A (https=)
NO (1) NO328305B1 (https=)
NZ (1) NZ571615A (https=)
PE (1) PE20030867A1 (https=)
PL (1) PL370657A1 (https=)
TW (1) TW200306839A (https=)
WO (1) WO2003066603A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761453B2 (en) 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
CN1875021A (zh) 2003-11-04 2006-12-06 默克公司 取代的萘啶酮衍生物
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (https=) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
CA2131101A1 (en) * 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20070265285A1 (en) 2007-11-15
ATE551329T1 (de) 2012-04-15
KR20040083501A (ko) 2004-10-02
BR0307461A (pt) 2004-11-09
US20050085493A1 (en) 2005-04-21
AU2003210212A1 (en) 2003-09-02
PL370657A1 (en) 2005-05-30
ES2384967T3 (es) 2012-07-16
CN1628104A (zh) 2005-06-15
EP1472234A1 (en) 2004-11-03
CO5601021A2 (es) 2006-01-31
KR100954626B1 (ko) 2010-04-27
US8552015B2 (en) 2013-10-08
CA2471974C (en) 2011-11-22
JP2005522439A (ja) 2005-07-28
EP1472234B1 (en) 2012-03-28
NO20043580L (no) 2004-09-21
PE20030867A1 (es) 2003-12-04
MY143958A (en) 2011-07-29
CN100579968C (zh) 2010-01-13
CA2471974A1 (en) 2003-08-14
AR038483A1 (es) 2005-01-19
NZ571615A (en) 2010-01-29
NO20043580D0 (no) 2004-08-27
JP4428479B2 (ja) 2010-03-10
NO328305B1 (no) 2010-01-25
WO2003066603A1 (en) 2003-08-14
EP2319839A1 (en) 2011-05-11
HK1079518A1 (zh) 2006-04-07
MXPA04007641A (es) 2004-11-10
ECSP045219A (es) 2004-09-28
JP2009149658A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
TW200306839A (en) Quinazolinone derivatives and their use as CB agonists
JP3814125B2 (ja) ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP3815966B2 (ja) ２−アリール−８−オキソジヒドロプリン誘導体、その製造方法および該化合物の中間体
JP5391351B2 (ja) ヘテロ二環式メタロプロテアーゼ阻害薬
AU722480B2 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
CN101460175A (zh) 用于fgf受体激酶抑制剂的组合物和方法
EP2799435A1 (en) Poly (adp-ribose) polymerase inhibitor
HUP9903560A2 (hu) Kinolin- és kinazolinszármazékok
JP2010520294A (ja) 複素環式部分を含有するメタロプロテアーゼ阻害剤
JP2006528685A (ja) 新規化合物
TW201443066A (zh) 經三氟甲基－取代之稠合嘧啶類及其用途
EP0991627B1 (en) Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same
JP2016513129A (ja) ベンジル−置換ピラゾロピリジンおよびその使用
JP2013505254A (ja) プロテインキナーゼ阻害のための新規化合物及びその治療的使用
CN115417867A (zh) 取代萘甲酰胺类衍生物及其医药用途
Rhee et al. Synthesis and cytotoxicity of 2-phenylquinazolin-4 (3H)-one derivatives
US8629272B2 (en) Tricyclic pyrimidine derivatives as wnt antagonists
CN102268000A (zh) 一类新型螺杂环化合物及其作为治疗剂的用途
US20110178078A1 (en) Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof
US20030158184A1 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU2007202781B2 (en) Quinazolinone derivatives and their use as CB agonists
HK1079518B (en) Quinazolinone derivatives and their use as cb agonists
US20060063774A1 (en) Phosphodiesterase inhibitor compounds and nitric oxide donors
JPWO1996032383A1 (ja) 酢酸アミド誘導体、その製法及びそれを含有する医薬組成物